7:30 PM - 8:30 PM EDT
Overview
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder leading to neuromuscular dysfunction, and approximately half of the cases of this disease are associated with malignancy. As such, optimal management of LEMS requires careful coordination among a variety of disciplines and specialties in health care to prevent progression of both LEMS and the underlying cancer.
This live Virtual Tumor Board® webcast is specifically designed to meet the needs of busy clinicians who treat patients with cancer and LEMS by providing a framework for diagnosis and treatment. Following presentations on current and emerging principles for detecting and managing LEMS, the faculty will discuss a series of challenging cases to highlight key issues and solutions in the real-world setting from the perspective of different specialties in cancer care.
Benefits of Attending
- Gain insight from expert faculty on how best to screen for and diagnose LEMS
- Learn the best treatment options for patients with LEMS
- Engage thought leaders as they discuss current treatment principles for LEMS
Target Audience
This educational activity is directed toward oncologists, neurologists, neuromuscular specialists, and nurses.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Review the pathophysiology and diagnostic criteria of Lambert-Eaton myasthenic syndrome (LEMS)
- Assess efficacy and safety data from pivotal trials evaluating therapeutic options to treat patients with LEMS, including cancer-related LEMS
- Implement proactive multidisciplinary strategies to monitor and mitigate treatment-related toxicities in patients with LEMS
- Apply practice-changing evidence to clinical scenarios of patients with cancer-related LEMS
